ENSYSCE BIOSCIENCES, INC. (ENSC) Scorecard
- 2026-Q2: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2026-Q1: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q4: Total return Lose; Revenue growth Lose; EPS growth Lose.
- 2025-Q3: Total return Lose; Revenue growth Lose; EPS growth Lose.
16/120
All 120 Win/Lose results shown below
Every strict quarterly win earns 1 point. A loss, tie, or unavailable scoring value earns 0.
Trailing 1 year (4 quarters): 0 wins, 12 lossesLast fetched: 4 Sept 2026
Complete point ledger
Each cell identifies the missing side explicitly.
| Quarter | Total return | Revenue growth | EPS growth |
|---|---|---|---|
| 2026-Q20/3 |
LoseENSC / S&P -46.20% / 15.20% |
LoseENSC / S&P -39.29% / 15.00% |
LoseENSC / S&P -37.47% / 50.40% |
| 2026-Q10/3 |
LoseENSC / S&P -41.41% / -4.33% |
LoseENSC / S&P -24.36% / 11.30% |
LoseENSC / S&P -52.62% / 27.70% |
| 2025-Q40/3 |
LoseENSC / S&P -61.18% / 2.65% |
LoseENSC / S&P -2.75% / 9.00% |
LoseENSC / S&P -70.13% / 13.40% |
| 2025-Q30/3 |
LoseENSC / S&P 6.28% / 8.12% |
LoseENSC / S&P 1.51% / 4.61% |
LoseENSC / S&P -91.76% / 13.45% |
| 2025-Q21/3 |
LoseENSC / S&P -12.89% / 10.94% |
WinENSC / S&P 415.58% / 4.83% |
LoseENSC / S&P -94.83% / 10.63% |
| 2025-Q11/3 |
LoseENSC / S&P -68.55% / -4.27% |
WinENSC / S&P 256.35% / 4.98% |
LoseENSC / S&P -91.35% / 10.57% |
| 2024-Q42/3 |
WinENSC / S&P 126.11% / 2.41% |
WinENSC / S&P 133.58% / 5.25% |
LoseENSC / S&P -81.00% / 6.15% |
| 2024-Q32/3 |
LoseENSC / S&P -52.57% / 5.89% |
WinENSC / S&P 40.41% / 5.89% |
WinENSC / S&P 3068.98% / 6.11% |
| 2024-Q21/3 |
LoseENSC / S&P -35.95% / 4.28% |
LoseENSC / S&P -51.96% / 5.38% |
WinENSC / S&P 25.89% / 5.12% |
| 2024-Q10/3 |
LoseENSC / S&P -25.47% / 10.56% |
LoseENSC / S&P -35.55% / 5.71% |
LoseENSC / S&P -35.00% / 5.59% |
| 2023-Q40/3 |
LoseENSC / S&P -23.19% / 11.69% |
LoseENSC / S&P -11.61% / 6.81% |
LoseENSC / S&P ENSC unavailable / 7.78% |
| 2023-Q31/3 |
LoseENSC / S&P -23.33% / -3.27% |
WinENSC / S&P 15.55% / 7.52% |
LoseENSC / S&P ENSC unavailable / -5.03% |
| 2023-Q20/3 |
LoseENSC / S&P -62.96% / 8.74% |
LoseENSC / S&P -17.93% / 9.50% |
LoseENSC / S&P ENSC unavailable / -8.57% |
| 2023-Q10/3 |
LoseENSC / S&P -46.00% / 7.50% |
LoseENSC / S&P -30.22% / 10.77% |
LoseENSC / S&P ENSC unavailable / -15.69% |
| 2022-Q40/3 |
LoseENSC / S&P -82.56% / 7.56% |
LoseENSC / S&P -28.54% / 11.88% |
LoseENSC / S&P ENSC unavailable / -17.99% |
| 2022-Q31/3 |
LoseENSC / S&P -75.23% / -4.88% |
WinENSC / S&P 17.85% / 13.47% |
LoseENSC / S&P ENSC unavailable / -1.41% |
| 2022-Q21/3 |
LoseENSC / S&P -23.86% / -16.10% |
WinENSC / S&P 88.05% / 13.71% |
LoseENSC / S&P ENSC unavailable / 11.04% |
| 2022-Q11/3 |
LoseENSC / S&P -75.74% / -4.60% |
WinENSC / S&P 17.00% / 15.97% |
LoseENSC / S&P ENSC unavailable / 42.23% |
| 2021-Q41/3 |
WinENSC / S&P 55.12% / 11.03% |
LoseENSC / S&P ENSC unavailable / 15.00% |
LoseENSC / S&P ENSC unavailable / 96.40% |
| 2021-Q30/3 |
LoseENSC / S&P -79.09% / 0.58% |
LoseENSC / S&P ENSC unavailable / 10.77% |
LoseENSC / S&P ENSC unavailable / 69.42% |
| 2021-Q21/3 |
WinENSC / S&P 10.78% / 8.55% |
LoseENSC / S&P ENSC unavailable / 6.58% |
LoseENSC / S&P ENSC unavailable / 51.81% |
| 2021-Q10/3 |
LoseENSC / S&P 5.19% / 6.17% |
LoseENSC / S&P ENSC unavailable / -1.06% |
LoseENSC / S&P ENSC unavailable / 7.39% |
| 2020-Q41/3 |
WinENSC / S&P 16.21% / 12.15% |
LoseENSC / S&P ENSC unavailable / -3.72% |
LoseENSC / S&P ENSC unavailable / -33.42% |
| 2020-Q30/3 |
LoseENSC / S&P -8.63% / 8.93% |
LoseENSC / S&P ENSC unavailable / -2.04% |
LoseENSC / S&P ENSC unavailable / -27.10% |
| 2020-Q20/3 |
LoseENSC / S&P 7.33% / 20.54% |
LoseENSC / S&P ENSC unavailable / -0.46% |
LoseENSC / S&P ENSC unavailable / -27.11% |
| 2020-Q11/3 |
WinENSC / S&P 4.70% / -19.60% |
LoseENSC / S&P ENSC unavailable / 3.47% |
LoseENSC / S&P ENSC unavailable / -14.75% |
| 2019-Q40/3 |
LoseENSC / S&P 1.76% / 9.07% |
LoseENSC / S&P ENSC unavailable / 5.36% |
LoseENSC / S&P ENSC unavailable / 2.99% |
| 2019-Q30/3 |
LoseENSC / S&P 0.69% / 1.70% |
LoseENSC / S&P ENSC unavailable / 5.02% |
LoseENSC / S&P ENSC unavailable / 0.21% |
| 2019-Q20/3 |
LoseENSC / S&P 1.34% / 4.30% |
LoseENSC / S&P ENSC unavailable / 6.64% |
LoseENSC / S&P ENSC unavailable / 8.65% |
| 2019-Q10/3 |
LoseENSC / S&P 2.20% / 13.65% |
LoseENSC / S&P ENSC unavailable / 8.12% |
LoseENSC / S&P ENSC unavailable / 14.29% |
| 2018-Q41/3 |
WinENSC / S&P 0.72% / -13.52% |
LoseENSC / S&P ENSC unavailable / 9.05% |
LoseENSC / S&P ENSC unavailable / 18.23% |
| 2018-Q30/3 |
LoseENSC / S&P 0.93% / 7.71% |
LoseENSC / S&P ENSC unavailable / 10.21% |
LoseENSC / S&P ENSC unavailable / 19.06% |
| 2018-Q20/3 |
LoseENSC / S&P 0.63% / 3.43% |
LoseENSC / S&P ENSC unavailable / 9.03% |
LoseENSC / S&P ENSC unavailable / 14.46% |
| 2018-Q10/3 |
LoseENSC / S&P ENSC unavailable / -0.76% |
LoseENSC / S&P ENSC unavailable / 7.68% |
LoseENSC / S&P ENSC unavailable / 12.46% |
| 2017-Q40/3 |
LoseENSC / S&P ENSC unavailable / 6.64% |
LoseENSC / S&P ENSC unavailable / 7.03% |
LoseENSC / S&P ENSC unavailable / 13.82% |
| 2017-Q30/3 |
LoseENSC / S&P ENSC unavailable / 4.48% |
LoseENSC / S&P ENSC unavailable / 5.68% |
LoseENSC / S&P ENSC unavailable / 17.57% |
| 2017-Q20/3 |
LoseENSC / S&P ENSC unavailable / 3.09% |
LoseENSC / S&P ENSC unavailable / 4.83% |
LoseENSC / S&P ENSC unavailable / 17.74% |
| 2017-Q10/3 |
LoseENSC / S&P ENSC unavailable / 6.07% |
LoseENSC / S&P ENSC unavailable / 3.67% |
LoseENSC / S&P ENSC unavailable / 13.32% |
| 2016-Q40/3 |
LoseENSC / S&P ENSC unavailable / 3.82% |
LoseENSC / S&P ENSC unavailable / 2.09% |
LoseENSC / S&P ENSC unavailable / 7.05% |
| 2016-Q30/3 |
LoseENSC / S&P ENSC unavailable / 3.85% |
LoseENSC / S&P ENSC unavailable / 0.20% |
LoseENSC / S&P ENSC unavailable / -3.15% |
Dividend-reinvested, split-adjusted total return
1Y · 2025-08-29 to 2026-08-27
| Metric | ENSC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -80.91% | 20.78% |
| Annualized return | -80.91% | 20.78% |
5Y · 2021-09-01 to 2026-08-27
| Metric | ENSC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 83.14% |
| Annualized return | -87.11% | 12.86% |
10Y · 2018-03-14 to 2026-08-27
| Metric | ENSC total return | S&P 500 Total Return Index |
|---|---|---|
| Total return | -100.00% | 319.30% |
| Annualized return | -67.90% | 15.41% |
Calculation rules
- window
- Latest 40 completed benchmark quarters; unavailable issuer evidence remains visible and scores 0.
- return Basis
- Issuer adjusted close reinvests distributions and normalizes splits; the S&P 500 Total Return Index is the direct benchmark.
- point Rule
- Strict same-quarter win = 1. Loss, tie or unavailable evidence = 0. No partial or subjective points.
- frequency
- Quarter endpoints only.
- fundamentals
- Trailing-four-quarter issuer revenue and EPS growth use the issuer's normalized government-filed facts.
- non Scoring
Snapshot captured 2026-09-04.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |